AstraZeneca's Tezspire received EU approval on October 22, 2025, for treating adults with severe chronic rhinosinusitis with nasal polyps, showing significant improvements over standard therapies. The approval highlights its effectiveness in reducing nasal polyp severity and the need for surgery, benefiting approximately 320 million affected worldwide.